Abstracts Archive - Page 112 of 2607 - ACR Meeting Abstracts

Abstract Number: 1280 • ACR Convergence 2025
Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
Yonatan Butbul Aviel¹, Arad Dotan², Dana Arnheim² and Cynthia Freiberg³, ¹Rambam Health Care Campus, Haifa, Israel, ²Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel, Tel Aviv, Israel, ³Maccabi Healthcare Services, Tel Aviv, Israel, Tel Aviv
Background/Purpose: During the COVID-19 pandemic there were reports of an increased association between COVID 19 and various autoimmune diseases (AID) in adults. This study aims…
Abstract Number: 1253 • ACR Convergence 2025
Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Nisha Sapkota¹, Chana Birnbaum², Henna Levitansky², Yevheniia Andriushchenko², Saadia Malik², Melissa Andrade², Sarang Choi² and Sima Terebelo², ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: When treating patients with rheumatological conditions, building a strong physician-patient relationship plays an important role in determining disease outcomes. The Routine Assessment of Patient…
Abstract Number: 1299 • ACR Convergence 2025
Pediatric Antiphospholipid Syndrome in a Large Tertiary Center
Rasha Elrefai, Marietta De Guzman, Jun Teruya, Vadim Kostousov, Amir Navaei and Olivia Kwan, Baylor College of Medicine, Houston, TX
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune condition defined as the presence of thrombotic events and/or pregnancy morbidity, accompanied by persistent antiphospholipid antibodies (aPLs). Pediatric…
Abstract Number: 1359 • ACR Convergence 2025
Comparative Safety Outcomes of Tofacitinib Versus Upadacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Maya Khasho¹, Ahmad Alomari², Reem Elmusa³ and Rafal Ali⁴, ¹University of central florida, Gainesville, FL, ²UCF- North Florida hospital, Gainesville, FL, ³UCF/ HCA - North florida hospital, Gainesville, FL, ⁴Jefferson Einstein Philadelphia, Lansdale, PA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease affecting synovial joints, often leading to joint destruction if untreated. Disease-modifying antirheumatic drugs (DMARDs), including Janus…
Abstract Number: 1324 • ACR Convergence 2025
Similar Negative Effects of Fatigue on Physical Activity in Persons with Rheumatoid Arthritis and Healthy Controls: A Patient-Control Study
Maartje Cox¹, Kyra Theunissen², Kenneth Meijer², Annick Timmermans³, Sofia Ramiro⁴, Annelies Boonen⁵ and Guy Plasqui², ¹Australian National Phenome Centre - Murdoch University, Booragoon, Western Australia, Australia, ²Maastricht University, Maastricht, Netherlands, ³Universiteit Hasselt, Hasselt, ⁴Leiden University Medical Center, Bunde, Netherlands, ⁵Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands
Background/Purpose: People with rheumatoid arthritis (pwRA) are prone to fall short of the World Health Organization’s physical activity (PA) recommendations due to perceived fatigue and…
Abstract Number: 1332 • ACR Convergence 2025
Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
Gilad Halpert¹, Yair Dankner², Eri Govrin¹, Abdulla Watad³, Omer Gendelman¹, Shlomo Segev¹, Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Shenkar College of Engineering and Design, Ramar Gan, Israel, ³Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…
Abstract Number: 1351 • ACR Convergence 2025
Are Glucocorticoids Associated with Worse Overall Survival among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
Deanna Jannat-Khah¹, Jeffrey Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne R. Bass¹, ¹Hospital For Special Surgery, New York, NY, ²Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York
Background/Purpose: Previous studies suggest that glucocorticoids are associated with worse survival in patients receiving immune checkpoint inhibitors (ICI). This is an important issue for Rheumatoid…
Abstract Number: 1273 • ACR Convergence 2025
Effectiveness of IV Cyclophosphamide and Mycophenolate Mofetil in the Treatment of Pediatric Systemic Lupus Erythematosus with Lupus Nephritis
adrienne katrin guiang-valerio, University of Santo Tomas Hospital, Mandaluyong, National Capital Region, Philippines
Background/Purpose: Lupus nephritis (LN) is more common in children (occurs in 50-82%) compared to adults. Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are both treatment options…
Abstract Number: 1317 • ACR Convergence 2025
The Association Between Insomnia and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 546,822 Patients
Mohamed Abdelsalam¹, Maryam Lasheen², Menat Alla Ayman Ali Mahdy³, Hadeer Hafez⁴, Nourhan Abouelella⁵, Mohamed Al-Adl⁶ and Mohamed Reda Awad⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁶Faculty of medicine Al-Azhar University Cairo, Nasr City, Egypt, ⁷Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Insomnia and rheumatoid arthritis (RA) are caught in a snowball effect, where chronic pain disrupts sleep and causes poor sleep quality, which in turn…
Abstract Number: 1327 • ACR Convergence 2025
Systematic Review of Mobility in Rheumatoid Arthritis with Digitally Measured Objective Assessment
Anna fishbein¹, Rachel Lawson², Veleka Allen¹, Xiaozhong Zhang³, Laura Chambre⁴, Stephen Ruhmel¹, Sophie Wilhelm¹, Fredric Marrache⁵, Maria Wiekowski¹, Markus Kohlmann⁶ and Jeffrey Curtis⁷, ¹Sanofi, Morristown, NJ, ²Sanofi, Earley, United Kingdom, ³Sanofi, Chengdu, China (People's Republic), ⁴Sanofi, Cambridge, MA, ⁵Sanofi, Gentilly, France, ⁶Sanofi, Frankfurt, Germany, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA) are less physically active than the general population, and these activity differences can be measured through digital devices. This…
Abstract Number: 1267 • ACR Convergence 2025
Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Leah Santacroce¹, Misti Paudel² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Patient Reported Outcomes (PROs) collected via a mobile health application (App) can provide valuable insight into the health of patients with Rheumatoid Arthritis (RA).…
Abstract Number: 1338 • ACR Convergence 2025
Short-Chain Fatty Acids and Their Gut Microbial Metabolic Pathways Distinguish Rheumatoid Arthritis in Discordant Monozygotic Twins
Rebecca Blank¹, Kevin Bu², Xinyuan Zhang³, Weixi Chen⁴, Ian Cunningham⁴, jeremy sokolove⁵, Lauren Lahey⁶, Adriana Heguy⁴, Rhina Medina⁴, Carles Ubeda⁷, Renuka Nayak⁸, Jiyuan Hu⁴, Adam Cantor⁹, Jakleen Lee⁹, Frances Williams¹⁰, Jose Clemente² and Jose Scher¹¹, ¹NYU Langone Health, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Kings College London, London, United Kingdom, ⁴NYU Grossman School of Medicine, New York, ⁵odyssey, Berwyn, PA, ⁶Stanford, Palo Alto, ⁷Fisabio, Madrid, ⁸University of California, San Francisco (UCSF), San Francisco, CA, ⁹Icahn School of Medicine, New York, ¹⁰Kings College London, London, ¹¹New York University School of Medicine, New York, NY
Background/Purpose: Although genetic factors have been identified in the pathogenesis of RA, the concordance rate in monozygotic (MZ) twins is low, suggesting that other factors…
Abstract Number: 1352 • ACR Convergence 2025
Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
Marco Di Paola¹, Edmund J MacLaughlin², Kathleen Methric³, Maurizio Muratore⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Fabiola Rosa Contaldo⁷, Fiorella Anna Lombardi¹, Paola Pisani¹, Francesco Conversano¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³BoneVue Diagnostics, Catonsville, MD, ⁴ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Autoimmune arthritis, including Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PA), are among the most common forms of inflammatory joint diseases. These conditions affect joints…
Abstract Number: 1348 • ACR Convergence 2025
Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Rieke Alten¹, Gerd Burmester², Marco Matucci-Cerinic³, Jens Gerwien⁴, Walid Fakhouri⁴, Samuel Ogwu⁴, Ewa Haladyj⁴, Inmaculada De La Torre⁴, Bruno Fautrel⁵ and AJ Fernandez⁴, ¹SCHLOSSPARK KLINK, Teaching Hospital of University Medicine Berlin, Department of Internal Medicine and Rheumatology, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³University San Raffaele Milano, Milano, Milan, Italy, ⁴Eli Lilly and Company, Indiana Polis, IN, ⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Here, we provide descriptive baseline characteristics and effectiveness outcomes of Baricitinib (BARI) and other ts/bDMARDs at 24-month (24M) in both European (EU) and non-European…
Abstract Number: 1319 • ACR Convergence 2025
The Association of Rheumatoid Arthritis in Patients with Vitiligo: Systematic Review and Meta-Analysis
Nattanicha Chaisrimaneepan¹, thunyaporn Khoruamklang², Pitchaporn Yingchoncharoen³, Tulaton Sodsri⁴ and Miriam Paz³, ¹Texas Tech University Health Sciences Center, Lubbock, TX, ²²Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, bangkok, Thailand, ³Texas Tech University Health Sciences Center, Lubbock, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand
Background/Purpose: Vitiligo is associated with many autoimmune diseases, but its association with rheumatic disease has not been well-defined. Therefore, we conducted a systematic review and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].